Database

Startups

Main Industry
Biotechnology
Main Product/Service
SOLUTION -
1. Genomic Tests
2. For Professionals
3. For Patients
4. For Biopharma
Founded Year
2013
Unified Business No.
54650959
Status
Active
Number of Employees
0
Total Paid-in Capital
455,080,000 (NT$)
Location of Company
Taiwan , Taipei City
Exit Status
Acquired(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Introduction
ACT Genomics is an award-winning cancer solution provider founded in 2014 by a small group of scientists from academia. With our name, ACT Genomics, reflecting our passion to “turn genomics into action”, we set out to apply academic theories in clinical p



More2 ↓

Similar Companies

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

Rephlmmune Biotechnology Inc.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and

ARCE THERAPEUTICS, INC.

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)
:::